文献速递肝病消化道肿瘤与早癌

血管包绕肿瘤簇(VETC)模式可预测肝细胞癌患者索拉非尼获益

Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2019-03-15

该研究在四家学术医院招募两个队列,探讨VETC模式能否预测索拉非尼获益。Kaplan-Meier分析显示,索拉非尼显著降低VETC+患者的死亡风险并延长总生存期和无复发生存期,而对VETC-患者无获益。机制研究提示VETC+与VETC-肝癌的LC3、pERK和EC-pERK水平相似,索拉非尼获益差异可能不源于Raf/MEK/ERK或VEGFA/VEGFR2/ERK信号激活或自噬诱导。结论认为索拉非尼可延长VETC+而非VETC-患者生存,VETC模式可作为索拉非尼获益的预测指标。

要点

  • 索拉非尼显著延长VETC+患者的OS和PRS,对VETC-患者无获益。
  • VETC+与VETC-肝癌的LC3、pERK和EC-pERK水平相似。
  • VETC模式可能作为肝细胞癌索拉非尼获益的预测指标。

核心结论

  • 索拉非尼可有效延长VETC+肝细胞癌患者的生存,但对VETC-患者无获益;VETC模式可能作为索拉非尼获益的预测指标。

研究设计与样本

  • 从四家学术医院招募两个队列,研究VETC+与VETC-患者接受索拉非尼治疗的生存获益。

主要发现

  • 队列1中VETC+患者索拉非尼治疗显著降低死亡风险并延长OS(P=0.004;HR=0.567)和PRS(P=0.001;HR=0.506)。
  • 队列2中VETC+患者索拉非尼治疗显著降低死亡风险并延长OS(P=0.005;HR=0.408)和PRS(P=0.002;HR=0.384)。
  • 队列1中VETC-患者索拉非尼治疗对OS(P=0.204;HR=0.761)和PRS(P=0.121;HR=0.728)无获益。
  • 队列2中VETC-患者索拉非尼治疗对OS(P=0.549;HR=1.221)和PRS(P=0.644;HR=1.161)无获益。
  • VETC+与VETC-肝癌的LC3、pERK和EC-pERK水平相似,且无论pERK/EC-pERK/LC3水平如何,VETC+患者索拉非尼获益均大于VETC-患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sorafenib is the most recommended first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response. We have demonstrated that a vascular pattern, named VETC (Vessels that Encapsulate Tumor Clusters), facilitates the release of whole tumor clusters into the bloodstream; VETC-mediated metastasis relies on vascular pattern, but not on migration and invasion of cancer cells. In this study, we aimed to explore whether vascular pattern could predict sorafenib benefit. Two cohorts of patients were recruited from four academic hospitals. The survival benefit of sorafenib treatment for patients with or without the VETC pattern (VETC+ /VETC- ) was investigated. Kaplan-Meier analyses revealed that sorafenib treatment significantly reduced death risk and prolonged overall survival (OS; in cohort 1/2, P = 0.004/0.005; hazard ratio [HR] = 0.567/0.408) and postrecurrence survival (PRS; in cohort 1/2, P = 0.001/0.002; HR = 0.506/0.384) in VETC+ patients. However, sorafenib therapy was not beneficial for VETC- patients (OS in cohort 1/2, P = 0.204/0.549; HR = 0.761/1.221; PRS in cohort 1/2, P = 0.121/0.644; HR = 0.728/1.161). Univariate and multivariate analyses confirmed that sorafenib treatment significantly improved OS/PRS in VETC+ , but not VETC- , patients. Further mechanistic investigations showed that VETC+ and VETC- HCCs displayed similar levels of light chain 3 (LC3) and phosphorylated extracellular signal-regulated kinase (ERK) in tumor tissues (pERK) or endothelial cells (EC-pERK), and greater sorafenib benefit was consistently observed in VETC+ HCC patients than VETC- irrespective of levels of pERK/EC-pERK/LC3, suggesting that the different sorafenib benefit between VETC+ and VETC- HCCs may not result from activation of Raf/mitogen-activated protein kinase kinase (MEK)/ERK and vascular endothelial growth factor (VEGF)A/VEGF receptor 2 (VEGFR2)/ERK signaling or induction of autophagy. Conclusion: Sorafenib is effective in prolonging the survival of VETC+ , but not VETC- , patients. VETC pattern may act as a predictor of sorafenib benefit for HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fang JH, Xu L, Shang LR, et al. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. Hepatology. 2019. PMID: 30506570. doi:10.1002/hep.30366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。